- RITXUMIAB RADIATION UNFOLDER TRIAL PUB MED SKIN
- RITXUMIAB RADIATION UNFOLDER TRIAL PUB MED LICENSE
- RITXUMIAB RADIATION UNFOLDER TRIAL PUB MED PLUS
Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin’s lymphoma. Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma nevertheless, most patients will have a relapse.
for the RELEVANCE Trial Investigators *.Alejandro Martin Garcia-Sancho, M.D., Ph.D.,.Original Article Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma List of authors. The most trusted, influential source of new medical knowledge and clinical best practices in the world.
RITXUMIAB RADIATION UNFOLDER TRIAL PUB MED LICENSE
Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care. RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.Ĭopyright © 2012 by the American College of Rheumatology.NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. Overall, RTX treatment was well tolerated. The median duration of response to RTX was 18 months. RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2 P < 0.001) up to month 24 (4.4 ± 4.6 P < 0.0001). Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% ), as well as at 3 months (92.9% versus 13.8% ), 6 months (71.4% versus 3.5% ), and 24 months (60.7% versus 3.5% ). Patients in the non-RTX group who did not respond to treatment could be switched to the RTX group. Patients were randomized to the non-RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids azathioprine or cyclophosphamide or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated.
RITXUMIAB RADIATION UNFOLDER TRIAL PUB MED SKIN
To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV).įifty-nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled.
0 kommentar(er)
